newsfilter
← Latest News
Business Wire·

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

-- Clinical Program Adds a Potentially Differentiated Oral Peptide IL-23 Receptor Inhibitor to Gilead’s Inflammation Portfolio -- -- HCXT-2001 Has Potential as a Monotherapy or in Combination with Other Gilead